This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Eli Lilly’s animal-health buy to face 27 May EC phase I deadline (corrects*)

By Dafydd Nelson ( April 19, 2010, 16:19 GMT | Insight) -- Pharmaceutical company Eli Lilly today notified its intended purchase of a portfolio of animal-health products owned by fellow drug-maker Pfizer to the European Commission for merger-control approval. An initial 27 May phase I decision deadline is expected to be set by the regulator.Pharmaceutical company Eli Lilly today notified its intended purchase of a portfolio of animal-health products owned by fellow drug-maker Pfizer to the European Commission for merger-control approval....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login